Company news

Novartis Ag (SIX:NOVN) news

Novartis Ag news releases on 6ix. Latest, Sep 29, 2026: CAS ประกาศความร่วมมือกับ Novartis เพื่อขับเคลื่อนระบบข้อมูลด้านปฏิกิริยาเคมีที่พร้อมรองรับ AI

Novartis Ag (SIX:NOVN) news

Press releases & updates

CAS ประกาศความร่วมมือกับ Novartis เพื่อขับเคลื่อนระบบข้อมูลด้านปฏิกิริยาเคมีที่พร้อมรองรับ AI

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Sironax Announces Option Exercise and Asset Purchase

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

Novartis receives Health Canada approval for (Pr)RHAPSIDO® (remibrutinib tablets) oral treatment for adults with CSU

Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Model N Appoints Thomas Gibbs to Board of Directors

Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Novartis AG Enterprise Technology Report 2025: Digital Transformation Strategies, Innovation Programs, Technology Initiatives, Partnerships, Investment & Acquisition, Network Map

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum

Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics